Royal Society of Chemistry, Inorganic Chemistry Frontiers, 2023
DOI: 10.1039/d3qi00157a
Full text: Unavailable
Diruthenium(ii,iii) paddlewheel carboxylates combine the pharmacological properties of the dimetallic center with those ascribed to the μ-bridged carboxylates, thus leading to novel, dual-acting anticancer metallodrugs.